Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
1.12
Oct 13 • 12:52 PM ET Dollar change-0.09 Percentage change(-7.05%)
Index
-
Market Cap
7.65M
Enterprise Value
-1.77M
Income
-21.24M
Sales
0.00M
Book/sh
0.90
Cash/sh
2.73
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Sep 25, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.25
P/C
0.41
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.58
Current Ratio
5.58
Debt/Eq
1.67
LT Debt/Eq
1.67
Option/Short
No / Yes
EPS (ttm)
-6.79
EPS next Y
-5.30
EPS next Q
-1.27
EPS this Y
69.37%
EPS next Y
-75.69%
EPS next 5Y
36.90%
EPS past 3/5Y
89.18% 38.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
15.38%
Sales Y/Y TTM
-
EPS Q/Q
-12.66%
Sales Q/Q
-
Insider Own
38.98%
Insider Trans
10.32%
Inst Own
34.43%
Inst Trans
19.95%
ROA
-110.10%
ROE
-365.70%
ROIC
-144.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-30.96%
SMA50
-51.37%
SMA200
-80.86%
Trades
Shs Outstand
6.15M
Shs Float
4.17M
52W High
36.00 -96.89%
52W Low
1.19 -5.88%
Volatility
8.69% 7.29%
ATR (14)
0.15
RSI (14)
17.99
Beta
0.77
Rel Volume
1.74
Avg Volume
76.48K
Volume
72,670
Perf Week
-24.83%
Perf Month
-44.00%
Perf Quarter
-71.34%
Perf Half Y
-63.93%
Perf YTD
-96.60%
Perf Year
-93.13%
Perf 3Y
-89.33%
Perf 5Y
-99.56%
Perf 10Y
-
Prev Close
1.21
Price
1.12
Change %
-7.05%
Date Action Analyst Rating Change Price Target Change
Aug-20-26Initiated Guggenheim Buy $9
Jan-29-26Downgrade H.C. Wainwright Buy → Neutral
Sep-08-26 07:00AM
Aug-27-26 09:00AM
Aug-11-26 10:11AM
07:00AM
Jul-29-26 07:00AM
07:01AM Loading…
Jun-24-26 07:01AM
07:00AM
May-12-26 07:00AM
Mar-03-26 07:00AM
Jan-29-26 07:24AM
Jan-28-26 11:48AM
07:00AM
Nov-12-25 07:01AM
07:00AM
Nov-10-25 07:00AM
07:00AM Loading…
Oct-14-25 07:00AM
Sep-02-25 07:00AM
Aug-19-25 02:42PM
Aug-12-25 07:00AM
Jul-08-25 07:00AM
Jun-25-25 07:00AM
Jun-12-25 07:00AM
May-14-25 07:00AM
Apr-17-25 07:00AM
Apr-02-25 12:00PM
Apr-01-25 07:00AM
Mar-27-25 07:00AM
Mar-05-25 07:00AM
Mar-04-25 07:00AM
Feb-19-25 07:00AM
04:05PM Loading…
Feb-03-25 04:05PM
Jan-14-25 07:00AM
Nov-21-24 08:00AM
Nov-20-24 04:05PM
Nov-13-24 07:00AM
Nov-07-24 07:00AM
Oct-30-24 10:11PM
04:50PM
07:00AM
Oct-28-24 04:05PM
Oct-16-24 08:00AM
Sep-03-24 08:00AM
Aug-12-24 04:10PM
Jul-09-24 07:30AM
Jul-08-24 08:00AM
Jul-01-24 08:00AM
Jun-27-24 08:00AM
07:06AM
Jun-26-24 04:05PM
May-28-24 07:53AM
May-21-24 09:48AM
May-13-24 04:05PM
May-07-24 08:00AM
Apr-24-24 08:00AM
Apr-10-24 03:30PM
Mar-28-24 11:53AM
07:00AM
Mar-13-24 08:00AM
Feb-28-24 06:57PM
Feb-13-24 08:00AM
Feb-07-24 04:05PM
Jan-22-24 08:00AM
Dec-11-23 07:30AM
Nov-09-23 07:00AM
Nov-02-23 09:15AM
Sep-06-23 07:30AM
Aug-31-23 07:30AM
Aug-11-23 07:01AM
Aug-10-23 04:05PM
06:24AM
Aug-09-23 07:30AM
06:26AM
Aug-08-23 06:28AM
Aug-07-23 06:35AM
Aug-04-23 07:14AM
Aug-03-23 07:15AM
Aug-02-23 07:52AM
Aug-01-23 06:51AM
Jul-31-23 06:44AM
Jul-28-23 07:58AM
Jul-27-23 07:10AM
Jul-26-23 01:12PM
Jul-25-23 07:16AM
Jul-24-23 07:12AM
Jul-21-23 07:23AM
Jul-20-23 06:55AM
Jul-19-23 07:10AM
Jul-18-23 06:53AM
Jul-17-23 07:10AM
Jul-14-23 06:50AM
Jul-13-23 07:02AM
Jul-12-23 07:22AM
Jul-11-23 06:08AM
Jul-10-23 06:56AM
Jul-05-23 06:46AM
Jul-03-23 06:50AM
Jun-30-23 06:52AM
Jun-29-23 06:49AM
Jun-28-23 06:58AM
Jun-27-23 06:46AM
CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
CEO & DirectorDr. A. Rachel Leheny Ph.D.
Chief Business Officer & Vice Chairman of the BoardMr. Eric W. Roberts
Chief Medical OfficerDr. Sudarshan Hebbar M.D.
M.B.A.Mr. Michael J. Dunn B.A.
Co-Founder and Scientific AdvisorDr. Anjana Rao Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Middleton Fred ADirectorJun 25 '26Buy0.80248,972199,9991,063,272Jun 29 08:45 AM